Assessment of Fetal Well-Being

Olds’ Maternal-Newborn Nursing & Women’s Health: Assessment of Fetal Well-Being

Twelfth Edition Chapter 15
Copyright © 2024, 2020, 2016 Pearson Education, Inc. All Rights Reserved


Psychologic Reactions to Antenatal Testing

  • Need for testing provokes fear and anxiety.

  • Patient has the option to refuse testing.

  • Ultrasound (US) has become almost routine.

    • Importance of counseling for shock and confusion experienced after testing.


Methods of Ultrasound Scanning

Transabdominal Ultrasound

  • Requires a full bladder to provide better visibility of structures.

  • This is a painless procedure lasting approximately 20–30 minutes.

Transvaginal Ultrasound

  • Requires an empty bladder.

  • More effective in assessing cervical length and funneling.

  • Patient is positioned in lithotomy position for clearer images, mainly utilized during the 2nd to 3rd trimester for better visibility of the fetus.


Ultrasound Assessments

First Trimester

  • Confirms the location of pregnancy.

  • Identifies fetal heart rate and fetal breathing movements.

  • Approximates gestational age.

  • Rules out a nonviable pregnancy.

    • Example: Measurement of the gestational age helps determine the position of the baby and the placenta.

Second & Third Trimester

  • Conducts a fetal anatomy scan:

    • Screens for genetic disorders.

    • Diagnoses fetal or congenital malformations.

    • Evaluates fetal growth.

    • Identifies fetal sex.

  • Measures Amniotic Fluid Index (AFI):

    • Evaluates fetal well-being.

    • Assesses fetal presentation.

    • Establishes placental location.


First Trimester Combined Screening

Nuchal Translucency Testing (NTT)

  • Ultrasound assesses fluid accumulation between the posterior cervical spine and overlying skin (nuchal fold).

  • Screening occurs between 11 weeks 0 days and 13 weeks 6 days.

  • Conducted in conjunction with a maternal serum blood test measuring plasma-protein A analyte levels (PAPP-A) and free beta hCG.

  • Note: This does not confirm a diagnosis; it screens for Down syndrome.

    • A definitive diagnosis requires invasive tests, such as amniocentesis.

Cell-Free Fetal DNA (cffDNA)

  • Maternal blood test with a 98% detection rate for fetal trisomy 21 and lower detection rates for trisomies 13 and 18.

  • Rh-negative mothers require RhoGAM because of the high invasiveness.

  • A positive result for Down syndrome necessitates further testing.


Second Trimester Assessments

Quad Screening

  • Most widely used test for screening Down syndrome (trisomy 21), trisomies 13 and 18, and neural tube defects (NTDs).

  • Provides serum assessment measuring:

    • Alpha-fetoprotein (AFP)

    • Human chorionic gonadotropin (hCG)

    • Unconjugated estriol (UE3)

    • Dimeric inhibin-A

  • Noninvasive assessment; does not confirm diagnosis.

  • Optimal testing occurs in the 2nd trimester, particularly at 16–18 weeks.


Third Trimester Fetal Surveillance

Fetal Movement Assessment (Fetal Kick Counts)

  • Initiated at 28 weeks gestation.

  • Mothers count movements at the same time daily, expecting 10 movements within 2-3 hours.

  • This is a noninvasive and cost-effective assessment of fetal central nervous system (CNS) functioning.

    • Vigorous movements indicate fetal well-being.

    • Concern for conditions like chronic placental insufficiency can arise from minimal to no movement.

    • Prenatal complications: Hypertension, diabetes, and renal disease can also reduce fetal movement.

Signs to Report to Healthcare Provider

  • Less than 10 movements in a 3-hour period.

  • Significantly reduced fetal movement levels.

  • Perception of decreased fetal movement over a 24-hour period.


Nonstress Test (NST)

  • A widely utilized method to evaluate fetal status.

    • Can be used alone or as part of a biophysical profile (BPP).

  • An adequately oxygenated fetus with an intact CNS should show accelerated fetal heart rate (FHR) in response to movements.

  • Note: There exists a high false-positive rate for this test.

Reactive NST

  • Defined as accelerations of FHR by 15 beats/min, lasting 15 seconds with each fetal movement.

  • Top of the NST strip records FHR; the bottom measures uterine activity tracing.

  • Affects how oxygenation is assessed for the fetus.

Advantages of NST

  • Quick to perform.

  • Easy interpretation.

  • Inexpensive.

  • Can be done in an office or clinic setting.

  • No known side effects.

Disadvantages of NST

  • Obtaining a suitable tracing can be challenging.

  • The woman must remain relatively still for at least 20 minutes.

  • High false-positive rate.


NST Results Interpretation

  • Reactive NST (desired result):

    • For fetuses over 32 weeks: At least two accelerations of FHR by 15 beats/min lasting 15 seconds or more over a 20-minute interval.

    • For preterm fetuses (under 32 weeks): At least 10 beats above baseline for 10 seconds in a 20-minute window.

  • Nonreactive NST:

    • Absence of FHR accelerations in response to fetal movement.

  • Baseline FHR example: 130 beats/min indicated with no accelerations.


Contraction Stress Test (CST)

  • Evaluates placental respiratory function (oxygen and carbon dioxide exchange).

  • Identifies fetuses at risk for intrauterine asphyxia.

  • Observes FHR response to contractions.

Disadvantages of CST

  • Can be time-consuming.

  • Yields high false-positive or equivocal results.

Contraindications for CST

  • Third-trimester bleeding from placenta previa.

  • Marginal abruptio placentae or unexplained vaginal bleeding.

  • History of classical cesarean incision.

  • Premature rupture of membranes.

  • Cervical insufficiency (incompetent cervix).

  • Cerclage in place or anomalies of maternal reproductive organs.

  • History of preterm labor if performed before term.

  • Multiple gestation.

Performing the CST

  • Requires presence of contractions; spontaneous contractions are unusual before labor onset.

    • Induction of contractions might require intravenous oxytocin (Pitocin) or breast stimulation.

  • Continuous electronic fetal monitoring to provide data on FHR and uterine contractions.

  • The goal is to observe three contractions in a 10-minute window.

Results of the CST
  • Negative CST with reactive NST desired: Three good-quality contractions lasting 40 or more seconds without late decelerations.

  • Positive CST indicates repetitive, persistent late decelerations with more than 50% of contractions.

  • Equivocal/Suspicious: Nonpersistent late decelerations or associated with tachysystole; implies baby won't tolerate labor well.


Amniotic Fluid Index

  • Decreased uteroplacental perfusion may lead to oligohydramnios.

  • Amniotic fluid volume determined by:

    • Fetal urine output.

    • Fetal swallowing.

  • AFI ≤ 5 mandates further evaluation; volume less than 5 cm correlates with poor pregnancy outcomes.


Biophysical Profile (BPP)

  • Assessment includes five fetal biophysical variables:

    • Fetal heart rate acceleration (NST).

    • Fetal breathing (via ultrasound).

    • Fetal movements (via ultrasound).

    • Fetal tone (via ultrasound).

    • Amniotic fluid volume (via ultrasound).

BPP Scoring Criteria

  • Score of 2 assigned for each normal finding; 0 for abnormal findings.

  • Total score maximum is 10.

  • Interpretation of scores:

    • 8-10: Low risk.

    • 6: Abnormal, possible acidemia.

    • < 4: Indicates inadequate oxygenation.


Indications for BPP

  • Decreased fetal movement.

  • Nonreactive NST.

  • Management of Intrauterine Growth Restriction (IUGR).

  • Preterm Labor.

  • Gestational Diabetes Mellitus (DM).

  • Hypertensive disorders.

  • Postterm pregnancies.

  • Premature Rupture of Membranes (PROM).


Doppler Flow Studies

  • Conducted in high-risk pregnancies to assess placental function and blood flow velocity within vessels.

  • Noninvasive assessment for both maternal and fetal circulation.

    • Measures Blood flow velocity:

    • Systolic/diastolic (S/D) ratio with normal decreases near term.

    • Studies reduced blood flow through the umbilical artery indicate risks.

Indications for Doppler Flow Study
  • Diagnosed IUGR.

  • Suspected late-term small for gestational age (SGA) due to unknown cause or hypertensive disorders/Pre-eclampsia.


Placental Maturity

  • Grading process via ultrasound measures changes in:

    • Basal layer.

    • Chorionic plate.

    • Placental substance.

  • Grading scale: 0 to 3;

    • Grade 3 indicates mature placenta with extensive calcifications implying inadequate placental function.

  • Factors causing accelerated placental maturity:

    • Maternal smoking.

    • Postterm pregnancy.

    • Preeclampsia.

    • Gestational diabetes.


Amniocentesis

  • Utilized for detecting genetic, metabolic, and DNA abnormalities.

  • Determines fetal lung maturity in the third trimester.

  • Can identify neural tube defects and presence of infections.

  • Ideally performed between 15-16 weeks, but can be performed anytime.

    • Diagnosis noted during 10-18 weeks, with 16 weeks being optimal.

    • Measures Lecithin/Sphingomyelin Ratio (LS ratio) to assess fetal lung maturity and also tests for alpha-fetoprotein.

Indications for Amniocentesis

  • Pregnant women aged 35 or older on their due date.

  • Couples with history of birth defects.

  • Pregnant women with any abnormal screening or genetic test results.

Procedure for Amniocentesis
  • Initial ultrasound locates the placental site and pockets of fluid.

  • Needle insertion involves feeling three levels of resistance as it passes through skin and uterine walls until reaching the amniotic cavity to withdraw fluid.

  • If the mother is Rh-negative, she requires Rhogam injection to prevent complications.

Risks and Side Effects of Amniocentesis
  • Transient vaginal spotting and cramping.

  • Possible amniotic fluid leakage.

  • Risk of Chorioamnionitis.

  • Higher rate of loss if performed early.


Chorionic Villus Sampling (CVS)

  • Used to detect genetic, metabolic, and DNA abnormalities.

  • Involves needle aspiration of chorionic villi from the placenta for first trimester diagnosis (usually at 10-12 weeks).

  • Cannot detect neural tube defects; recommended to proceed with quad screening for that.

Risks of CVS

  • Potential for spontaneous abortion.

  • Risk of fetal limb reduction defects.

  • Difficulty obtaining tissue samples.

  • Possible complications include rupture of membranes, leakage of amniotic fluid, vaginal spotting or bleeding, Chorioamnionitis, and intrauterine infections.

Benefits of CVS

  • Provides earlier diagnosis than Amniocentesis.

  • Can detect a range of conditions such as:

    • Fetal karyotype.

    • Hemoglobinopathies.

    • Phenylketonuria (PKU).

    • Down syndrome.

    • Duchenne muscular dystrophy.

    • Factor IX deficiency.

    • Early sex determination (within 24 hours to 1 week).